Comparing NRx Pharmaceuticals (NASDAQ:NRXP) and BeOne Medicines (NASDAQ:ONC)

BeOne Medicines (NASDAQ:ONC) and NRx Pharmaceuticals (NASDAQ:NRXP) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Risk & Volatility

BeOne Medicines has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for BeOne Medicines and NRx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0	2	12	3	3.06
NRx Pharmaceuticals	2	0	5	0	2.43

BeOne Medicines currently has a consensus price target of $404.14, suggesting a potential upside of 12.87%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,089.66%. Given NRx Pharmaceuticals’ higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than BeOne Medicines.

Insider and Institutional Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares BeOne Medicines and NRx Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	7.36	$286.93 million	$5.68	63.04
NRx Pharmaceuticals	$1.23 million	102.09	-$28.62 million	($0.55)	-5.27

BeOne Medicines has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeOne Medicines and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Summary

BeOne Medicines beats NRx Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.